Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Acasti Pharma Inc ACST

Healthcare
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the... see more

NDAQ:ACST - Post Discussion

Acasti Pharma Inc > Amarin loses court battle to generics
View:
Comment by Francine01 on Mar 30, 2020 5:23pm
Still dont know if good or bad news for Acasti, they were not in the cv market and could now produce generic of Amarin and claim cv benefits !? I think I could be good news, because OM3 market will shifts to diabetics. In any case, there will be an appeal and will be ruled in a year.
Comment by Stormdog01 on Mar 30, 2020 5:38pm
So far ACST down 8% after-hours. Totally agree they will most likely go and appeal. I think AMRN generic would bring some downward pressure on overall OM3 treatment market prices, but not so significant for ACST given the diabetic angle. I think it does however put a little bit more pressure on ACST's need to achieve statistical significance on Hba1c secondary endpoint, which I believe they ...more  
Comment by Rosmorduc on Mar 30, 2020 7:52pm
ACST is actually up after hours. ACST wins, CAPRE will reflect its true might shortly. You wait and see. You will believe when it's all said and done.  10 bagger here. 
Acasti Pharma Inc